Publicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria Biodonostia (11)

2023

  1. Validation of Rapid and Economic Colorimetric Nanoparticle Assay for SARS-CoV-2 RNA Detection in Saliva and Nasopharyngeal Swabs

    Biosensors, Vol. 13, Núm. 2

2021

  1. Integrated mrna and mirna transcriptomic analyses reveals divergent mechanisms of sunitinib resistance in clear cell renal cell carcinoma (Ccrcc)

    Cancers, Vol. 13, Núm. 17

2020

  1. An integrative omics approach reveals involvement of BRCA1 in hepatic metastatic progression of colorectal cancer

    Cancers, Vol. 12, Núm. 9, pp. 1-24

  2. Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study

    International Journal of Cancer, Vol. 147, Núm. 5, pp. 1315-1324

  3. The urinary transcriptome as a source of biomarkers for prostate cancer

    Cancers, Vol. 12, Núm. 2

2018

  1. Mutational profiling can identify laryngeal dysplasia at risk of progression to invasive carcinoma

    Scientific Reports, Vol. 8, Núm. 1

  2. Noncoding RNA Expression and Targeted Next-Generation Sequencing Distinguish Tubulocystic Renal Cell Carcinoma (TC-RCC) from Other Renal Neoplasms

    Journal of Molecular Diagnostics, Vol. 20, Núm. 1, pp. 34-45

  3. Spatial intratumoural heterogeneity in the expression of GIT1 is associated with poor prognostic outcome in oestrogen receptor positive breast cancer patients with synchronous lymph node metastases

    F1000Research, Vol. 6

2016

  1. New concepts in cancer biomarkers: Circulating miRNAs in liquid biopsies

    International Journal of Molecular Sciences, Vol. 17, Núm. 5

2015

  1. The circulating transcriptome as a source of non-invasive cancer biomarkers: Concepts and controversies of non-coding and coding RNA in body fluids

    Journal of Cellular and Molecular Medicine, Vol. 19, Núm. 10, pp. 2307-2323

2012

  1. Bortezomib action in multiple myeloma: MicroRNA-mediated synergy (and miR-27a/CDK5 driven sensitivity)?

    Blood Cancer Journal